What is he best known for?
The fields of study he is best known for:
- Enzyme
- Organic chemistry
- Internal medicine
His main research concerns Folate receptor, Conjugate, Biochemistry, Chelation and Click chemistry.
His Folate receptor study incorporates themes from Specific activity, Biodistribution, Radionuclide therapy, Positron emission tomography and Spect imaging.
Roger Schibli has included themes like Radiochemistry and DOTA in his Radionuclide therapy study.
His Chelation research includes themes of Substitution reaction, Ligand, Metal, Stereochemistry and Amine gas treating.
Click chemistry is a subfield of Combinatorial chemistry that Roger Schibli explores.
As a part of the same scientific family, Roger Schibli mostly works in the field of In vitro, focusing on Distribution and, on occasion, Cancer research, Cancer and Folic acid.
His most cited work include:
- A Novel Organometallic Aqua Complex of Technetium for the Labeling of Biomolecules: Synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in Aqueous Solution and Its Reaction with a Bifunctional Ligand (546 citations)
- Synthesis and properties of boranocarbonate: a convenient in situ CO source for the aqueous preparation of [(99m)Tc(OH(2))3(CO)3]+. (346 citations)
- Metal chelating systems synthesized using the copper(I) catalyzed azide-alkyne cycloaddition. (313 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are In vitro, Biodistribution, Biochemistry, Folate receptor and Stereochemistry.
While the research belongs to areas of In vitro, Roger Schibli spends his time largely on the problem of Pathology, intersecting his research to questions surrounding Positron emission tomography and Preclinical imaging.
His Biodistribution research focuses on Pharmacology and how it connects with Albumin and Kidney.
His Folate receptor study integrates concerns from other disciplines, such as Pemetrexed, Cancer research and Radionuclide therapy.
His Stereochemistry study combines topics from a wide range of disciplines, such as Medicinal chemistry, Chelation, Ligand, Rhenium and Derivative.
His Chelation research is multidisciplinary, incorporating elements of Combinatorial chemistry and Click chemistry.
He most often published in these fields:
- In vitro (36.70%)
- Biodistribution (27.96%)
- Biochemistry (22.52%)
What were the highlights of his more recent work (between 2017-2021)?
- Biodistribution (27.96%)
- In vitro (36.70%)
- Receptor (18.06%)
In recent papers he was focusing on the following fields of study:
Biodistribution, In vitro, Receptor, Radioligand and Cancer research are his primary areas of study.
The various areas that Roger Schibli examines in his Biodistribution study include Ex vivo, Molecular biology, Albumin, Pharmacology and Folate receptor.
His work focuses on many connections between Folate receptor and other disciplines, such as Pet tracer, that overlap with his field of interest in Biochemistry.
Roger Schibli combines subjects such as Radiochemistry and Biophysics with his study of In vitro.
His biological study spans a wide range of topics, including Insulinoma, Stereochemistry, Positron emission tomography and Peptidomimetic, Peptide.
His Cancer research research focuses on Radionuclide therapy and how it relates to DOTA, Chelation, Therapeutic effect, Specific activity and Radiation therapy.
Between 2017 and 2021, his most popular works were:
- Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. (41 citations)
- Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. (41 citations)
- Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties to Improve Prostate Cancer Therapy (35 citations)
In his most recent research, the most cited papers focused on:
- Enzyme
- Organic chemistry
- Internal medicine
Roger Schibli mainly focuses on Biodistribution, Radioligand, Radionuclide therapy, Prostate cancer and In vitro.
His research integrates issues of Ex vivo, Brachytherapy, Receptor, Antagonist and Stereochemistry in his study of Biodistribution.
Roger Schibli conducts interdisciplinary study in the fields of Stereochemistry and Conjugate through his works.
His Radionuclide therapy research incorporates elements of Yield, Extraction, Chelation, DOTA and Radiochemistry.
His research in In vitro is mostly focused on Viability assay.
His research investigates the connection between Nuclear medicine and topics such as Urinary bladder that intersect with issues in Folate receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
